Stockreport

Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults

Crinetics Pharmaceuticals, Inc.  (CRNX) 
Last crinetics pharmaceuticals, inc. earnings: 3/9 04:10 pm Check Earnings Report
PDF PALSONIFY is the first once-daily, oral therapy approved to treat acromegaly in the European Union Approval based on strength of data from two pivotal Phase 3 studies s [Read more]